Atea Pharmaceuticals (AVIR) Operating Leases (2022 - 2025)

Atea Pharmaceuticals' Operating Leases history runs 4 years deep, the most recent figure standing at $213000.0 for Q3 2025.

• In Q3 2025, Operating Leases fell 79.62% year-over-year to $213000.0; the TTM figure through Sep 2025 stood at $213000.0 (down 79.62% YoY), while the FY2024 annual figure was $842000.0, down 48.72% from the prior year.
• Operating Leases was $213000.0 for Q3 2025 at Atea Pharmaceuticals, down from $425000.0 in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $2.8 million in Q2 2022 to a low of $213000.0 in Q3 2025.
• Historically, Operating Leases has averaged $1.6 million across 4 years, with a median of $1.6 million in 2023.
• The sharpest annual moves came in 2023 and 2025: Operating Leases slipped 19.83% in 2023, then tumbled 79.62% in 2025.
• A 4-year view of Operating Leases shows it stood at $2.4 million in 2022, then tumbled by 31.67% to $1.6 million in 2023, then plunged by 48.72% to $842000.0 in 2024, then tumbled by 74.7% to $213000.0 in 2025.
• The last three Operating Leases figures came in at $213000.0 (Q3 2025), $425000.0 (Q2 2025), and $634000.0 (Q1 2025), per Business Quant data.